Amgen Inc (AMGN)

140.59
0.60 0.42
NASDAQ : Health Care
Prev Close 141.19
Open 140.83
Day Low/High 138.83 / 141.10
52 Wk Low/High 130.09 / 181.81
Volume 4.39M
Avg Volume 3.83M
Exchange NASDAQ
Shares Outstanding 743.92M
Market Cap 107.95B
EPS 9.20
P/E Ratio 12.83
Div & Yield 4.00 (2.80%)

Latest News

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.

Arrowhead Pharma Shares Destroyed by Development Announcement

Arrowhead Pharma Shares Destroyed by Development Announcement

The company has seen shares fall 60% since market's close Tuesday.

Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016

Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016

Sub-Analysis From Phase 3 TOWER Study Compares Health-Related Quality of Life of BLINCYTO® (Blinatumomab) to Standard of Care Chemotherapy

'Mad Money' Lightning Round: American Electric Power, Amgen, Dow Chemical

'Mad Money' Lightning Round: American Electric Power, Amgen, Dow Chemical

Jim Cramer finds reasons to like AEP, AMGN, DOW and HEI.

Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years

Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years

This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study

Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study

STRIVE Study Met its Primary Endpoint, Adding to Body of Episodic Migraine Prevention Data

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration

Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer

Repatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease

Repatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease

Nearly Two-Thirds of Patients Experienced Plaque Regression With Repatha on Top of Optimized Statin Therapy

New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine

New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine

Scientists From Premier Educational and Research Institutions Reveal What the Future may Look Like

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis

Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis

Romosozumab Data at the ACR/ARHP Annual Meeting Show Significant Bone Mineral Density Gains at the Lumbar Spine, Total Hip and Femoral Neck Compared to Placebo at Six and 12 Months

European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

First Treatment Advance for Secondary Hyperparathyroidism in More Than a Decade and First Intravenous Calcimimetic to Help Healthcare Providers Lower Key Lab Values

Check Out These 15 Stocks With Solid Dividend Yields

Check Out These 15 Stocks With Solid Dividend Yields

Here are 15 stocks that boast solid dividend yields and are growing earnings.

How to Play Rising Treasury Yields

How to Play Rising Treasury Yields

Check out these 15 stocks that boast solid dividend yields and are growing earnings.

Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma

Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma

Initial Phase 3 Registrational Study Planned in Relapsed or Refractory Multiple Myeloma Patients

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.

Amgen Is a Total Battleground

Amgen Is a Total Battleground

While Amgen has a strong pipeline, it may not be enough to replace the legacy treatments that are losing market share.

Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases

Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases

21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis

FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis

FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis

First and Only Systemic Drug Approved in the U.S. to Treat Children Affected by This Serious Inflammatory Disease

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.